Komori
Share Issuance and Disposal4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice Regarding the Monthly Exercise Status of the 58th and 66th Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Provisions)

In July 2026, 37,940 of the 66th Stock Acquisition Rights were exercised, and 3,794,000 new shares were delivered. No 58th Stock Acquisition Rights were exercised.

Worth reading
69In focus
Scored from 3 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
3794000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Monthly exercise status of stock acquisition rights with an exercise price adjustment clause

Who receives how much

66th Stock Acquisition Rights: 3,794,000 new shares; 58th Stock Acquisition Rights: 0 shares

Series 66 Stock Acquisition Rights: EVO FUND; Series 58 Stock Acquisition Rights: CVI Investments, Inc.

The lower thin line represents the existing number of shares to which these shares will be added.

発行済株式総数

Exercise ratio subject to exercise restrictions: 7.8% (3,794,000 shares delivered for all series combined / 48,855,455 listed shares outstanding as of the payment date for the issuance)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
The exercise price for both the 66th and 58th Stock Acquisition Rights during the target month was ¥84. Details of the adjustment clause and the floor price: Not disclosed
Number of Stock Acquisition Rights
66th Stock Acquisition Rights: total issued, 200,000; unexercised at the end of the month preceding the target month, 158,450; unexercised at the end of the target month, 120,510. 58th Stock Acquisition Rights: total issued, 20,000; unexercised at the end of the month preceding the target month, 20,000; unexercised at the end of the target month, 20,000
Most recent equity financing
Issued on 1 June 2022: 58th Stock Acquisition Rights (issue price and total amount: Not disclosed), Issued on 12 August 2025: 65th through 67th Stock Acquisition Rights, including the 66th Stock Acquisition Rights (issue price and total amount: Not disclosed)
Details of issuance or disposal
ItemDetails
Type of issuance or disposalMonthly exercise status of stock acquisition rights with an exercise price adjustment clause
Number of shares to be issued or disposed of66th Stock Acquisition Rights: 3,794,000 new shares; 58th Stock Acquisition Rights: 0 shares
Intended allotteeSeries 66 Stock Acquisition Rights: EVO FUND; Series 58 Stock Acquisition Rights: CVI Investments, Inc.
Dilution RateExercise ratio subject to exercise restrictions: 7.8% (3,794,000 shares delivered for all series combined / 48,855,455 listed shares outstanding as of the payment date for the issuance)
Total number of issued shares76,434,210 shares → Not disclosed
Exercise priceThe exercise price for both the 66th and 58th Stock Acquisition Rights during the target month was ¥84. Details of the adjustment clause and the floor price: Not disclosed
Number of Stock Acquisition Rights66th Stock Acquisition Rights: total issued, 200,000; unexercised at the end of the month preceding the target month, 158,450; unexercised at the end of the target month, 120,510. 58th Stock Acquisition Rights: total issued, 20,000; unexercised at the end of the month preceding the target month, 20,000; unexercised at the end of the target month, 20,000
Most recent equity financingIssued on 1 June 2022: 58th Stock Acquisition Rights (issue price and total amount: Not disclosed), Issued on 12 August 2025: 65th through 67th Stock Acquisition Rights, including the 66th Stock Acquisition Rights (issue price and total amount: Not disclosed)
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The 58th Stock Acquisition Rights became deemed “MSCBs, etc.” under the Tokyo Stock Exchange’s Listing Regulations in connection with the issuance of the 65th through 67th Stock Acquisition Rights dated 12 August 2025, and therefore became subject to disclosure of monthly exercise status. No reason for the exercise of the 66th Stock Acquisition Rights was disclosed.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 58th and 66th Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Provisions) | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori